000 | 02005 a2200625 4500 | ||
---|---|---|---|
005 | 20250518054853.0 | ||
264 | 0 | _c20200707 | |
008 | 202007s 0 0 eng d | ||
022 | _a1538-8514 | ||
024 | 7 |
_a10.1158/1535-7163.MCT-19-0170 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aHao, Huai-Xiang | |
245 | 0 | 0 |
_aTumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers. _h[electronic resource] |
260 |
_bMolecular cancer therapeutics _c12 2019 |
||
300 |
_a2368-2380 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 | _aCell Line, Tumor |
650 | 0 | 4 | _aDisease Models, Animal |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMice |
650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
650 | 0 | 4 |
_aProtein Tyrosine Phosphatase, Non-Receptor Type 11 _xantagonists & inhibitors |
650 | 0 | 4 |
_aProto-Oncogene Proteins p21(ras) _xgenetics |
650 | 0 | 4 | _aSignal Transduction |
650 | 0 | 4 |
_aTachykinins _xantagonists & inhibitors |
650 | 0 | 4 | _aXenograft Model Antitumor Assays |
700 | 1 | _aWang, Hongyun | |
700 | 1 | _aLiu, Chen | |
700 | 1 | _aKovats, Steven | |
700 | 1 | _aVelazquez, Roberto | |
700 | 1 | _aLu, Hengyu | |
700 | 1 | _aPant, Bhavesh | |
700 | 1 | _aShirley, Matthew | |
700 | 1 | _aMeyer, Matthew J | |
700 | 1 | _aPu, Minying | |
700 | 1 | _aLim, Joanne | |
700 | 1 | _aFleming, Michael | |
700 | 1 | _aAlexander, LeighAnn | |
700 | 1 | _aFarsidjani, Ali | |
700 | 1 | _aLaMarche, Matthew J | |
700 | 1 | _aMoody, Susan | |
700 | 1 | _aSilver, Serena J | |
700 | 1 | _aCaponigro, Giordano | |
700 | 1 | _aStuart, Darrin D | |
700 | 1 | _aAbrams, Tinya J | |
700 | 1 | _aHammerman, Peter S | |
700 | 1 | _aWilliams, Juliet | |
700 | 1 | _aEngelman, Jeffrey A | |
700 | 1 | _aGoldoni, Silvia | |
700 | 1 | _aMohseni, Morvarid | |
773 | 0 |
_tMolecular cancer therapeutics _gvol. 18 _gno. 12 _gp. 2368-2380 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1158/1535-7163.MCT-19-0170 _zAvailable from publisher's website |
999 |
_c30032009 _d30032009 |